Switch theme
Sign up to access all valuation multiples
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
1994
202
LTM Revenue $1.0M
Last FY EBITDA -$157M
$333M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Omeros has a last 12-month revenue (LTM) of $1.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Omeros achieved revenue of n/a and an EBITDA of -$157M.
Omeros expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Omeros valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$157M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$158M | XXX | -$169M | XXX | XXX | XXX |
| EBIT Margin | -15287% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$150M | XXX | -$157M | XXX | XXX | XXX |
| Net Margin | -14459% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $184M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Omeros's stock price is $3.
Omeros has current market cap of $181M, and EV of $333M.
See Omeros trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $333M | $181M | XXX | XXX | XXX | XXX | $-2.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Omeros has market cap of $181M and EV of $333M.
Omeros's trades at n/a EV/Revenue multiple, and -2.1x EV/EBITDA.
Equity research analysts estimate Omeros's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Omeros has a P/E ratio of -1.2x.
See valuation multiples for Omeros and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $181M | XXX | $181M | XXX | XXX | XXX |
| EV (current) | $333M | XXX | $333M | XXX | XXX | XXX |
| EV/Revenue | 321.8x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.1x | XXX | XXX | XXX |
| EV/EBIT | -2.1x | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | 536.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.2x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOmeros's last 12 month revenue growth is 5983%
Omeros's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
Omeros's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Omeros's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Omeros and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5983% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Omeros acquired XXX companies to date.
Last acquisition by Omeros was XXXXXXXX, XXXXX XXXXX XXXXXX . Omeros acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Omeros founded? | Omeros was founded in 1994. |
| Where is Omeros headquartered? | Omeros is headquartered in United States of America. |
| How many employees does Omeros have? | As of today, Omeros has 202 employees. |
| Who is the CEO of Omeros? | Omeros's CEO is Dr. Gregory A. Demopulos,M.D.. |
| Is Omeros publicy listed? | Yes, Omeros is a public company listed on NAS. |
| What is the stock symbol of Omeros? | Omeros trades under OMER ticker. |
| When did Omeros go public? | Omeros went public in 2009. |
| Who are competitors of Omeros? | Similar companies to Omeros include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Omeros? | Omeros's current market cap is $181M |
| What is the current revenue of Omeros? | Omeros's last 12 months revenue is $1.0M. |
| What is the current revenue growth of Omeros? | Omeros revenue growth (NTM/LTM) is 5983%. |
| What is the current EV/Revenue multiple of Omeros? | Current revenue multiple of Omeros is 321.8x. |
| Is Omeros profitable? | Yes, Omeros is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
